Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2006

01-05-2006 | Research Articles

Risk factors related to operative morbidity in patients undergoing gastrectomy for gastric cancer

Authors: A. Gil-Rendo, Hernández-Lizoain, F. Martínez-Regueira, A. Sierra Martínez, F. Rotellar Sastre, M. Cervera Delgado, V. Valentí Azcarate, C. Pastor Idoate, J. Álvarez-Cienfuegos

Published in: Clinical and Translational Oncology | Issue 5/2006

Login to get access
Metadata
Title
Risk factors related to operative morbidity in patients undergoing gastrectomy for gastric cancer
Authors
A. Gil-Rendo
Hernández-Lizoain
F. Martínez-Regueira
A. Sierra Martínez
F. Rotellar Sastre
M. Cervera Delgado
V. Valentí Azcarate
C. Pastor Idoate
J. Álvarez-Cienfuegos
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Clinical and Translational Oncology / Issue 5/2006
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-006-0182-x

Other articles of this Issue 5/2006

Clinical and Translational Oncology 5/2006 Go to the issue

Original Articles

Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer

Correspondence

Clearance of methotrexate by means of hemofiltration in a patient with osteosarcoma

Research Articles

Patterns of care for brachytherapy in Europe results in Spain

Educational Series

The proteasome: a novel target for anticancer therapy

Educational Series

Mouse models in oncogenesis and cancer therapy

Educational Series

Molecular biology of exocrine pancreatic cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits